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Abstract
The relatively new field of onco-metabolomics attempts to identify relationships between various cancer phenotypes and
global metabolite content. Previous metabolomics studies utilized either nuclear magnetic resonance spectroscopy or gas
chromatography/mass spectrometry, and analyzed metabolites present in urine and serum. However, direct metabolomic
assessment of tumor tissues is important for determining altered metabolism in cancers. In this respect, the ability to obtain
reliable data from archival specimens is desirable and has not been reported to date. In this feasibility study, we
demonstrate the analysis of polar metabolites extracted directly from ten formalin-fixed, paraffin-embedded (FFPE)
specimens, including five soft tissue sarcomas and five paired normal samples. Using targeted liquid chromatography-
tandem mass spectrometry (LC/MS/MS) via selected reaction monitoring (SRM), we detect an average of 106 metabolites
across the samples with excellent reproducibility and correlation between different sections of the same specimen.
Unsupervised hierarchical clustering and principal components analysis reliably recovers a priori known tumor and normal
tissue phenotypes, and supervised analysis identifies candidate metabolic markers supported by the literature. In addition,
we find that diverse biochemical processes are well-represented in the list of detected metabolites. Our study supports the
notion that reliable and broadly informative metabolomic data may be acquired from FFPE soft tissue sarcoma specimens, a
finding that is likely to be extended to other malignancies.
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Introduction
Metabolomics is the study of the metabolite repertoire with
respect to different physiological environments, tissue types, or
cells [1,2]. Analogous to genomics, transcriptomics, or proteomics,
it holds great promise in the quest for biomarker discovery,
particularly in oncology since cancer cells harbor an altered state
of metabolism according to the Warburg effect [3].
The low per-sample cost of performing LC/MS/MS in SRM
mode, or nuclear magnetic resonance spectroscopy (NMR) makes
metabolomic biomarker investigation particularly appealing [4].
The sensitivity and specificity of both technologies, particularly
mass spectrometry have improved dramatically in recent years,
leading to the publication of a number of studies, mostly profiling
urine and serum specimens [4]. Although clinically useful
information has come out of this work, one shortcoming of the
field is a lack of research on tissue metabolites [5]. It has been
shown that the tumor microenvironment places unusual stresses
on cells and leads to a shift in cellular energy production and
utilization. The rate of glycolysis has been shown to increase in
tumors resulting in high lactate levels, and high concentrations of
alanine and ammonium are also observed in various malignancies
as a result of elevated glutamine degradation [6–8]. Therefore,
there is reason to believe that studying the biochemical
intermediates and end products within tumor tissue samples
would enhance our understanding of cancer biology.
As in the other ‘‘omics’’ fields, metabolomics would greatly
benefit from the ability to utilize formalin-fixed and paraffin-
embedded (FFPE) tissue specimens acquired during routine
medical care. Because of their widespread availability and long
term stability, accurately profiling the metabolite content of these
tumor samples could accelerate the rate of discovery of clinically
useful metabolomic biomarkers.
While there is literature on LC/MS/MS based metabolomic
profiling, to our knowledge, there have been no publications on
the use FFPE tissue [1,2,9,10]. In this pilot study, we examine the
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MS to profile FFPE specimens. We examine the degree to which
malignant and non-malignant tissues can be distinguished by
metabolite content, and we comment on the diversity of
biochemical processes than can be probed with this method.
The results of this work demonstrate that metabolomic studies of
archival cancer specimens may yield reliable data and could aid
investigators in identifying clinically and biologically meaningful
biomarkers.
Results
Study Work Flow
A flow chart in Figure 1 summarizes the LC/MS/MS protocol
with a complete methods description presented in the materials
and methods section. We profiled a set of five formalin-fixed,
paraffin-embedded soft tissue sarcoma specimens and five paired
normal tissue samples by LC/MS/MS. Details on the specimen
age and tissue type are presented in Table 1. All paraffin blocks
contain tissue derived from surgical resection procedures. The
specimens are all dated from 2004, 2005, or 2006 and one patient
received radiation and chemotherapy prior to surgery. As this
study aims to demonstrate feasibility and reliability of data
acquisition, clinical variables aside from tissue type were not
considered. To assess the biological reproducibility we ran LC/
MS/MS on each of two independent sections from every paraffin
block. In addition, for every section, we performed three
independent injections to determine assay reproducibility.
Metabolite Detection
Upon acquiring raw data, we observed that out of the 249
compounds screened for by SRM, the number of unique
metabolites robustly detected ranged from 74 to 143 across the
samples with a mean value of 106 and represented several
metabolic pathways. Interestingly, there is a trend towards higher
metabolite detection rates in the tumor samples. Compared to
results from unrelated experiments with fresh frozen tissue using
the same platform, these numbers are approximately 40% lower,
which is expected when analyzing harshly treated and aged
specimens. Because frozen tissue from the patients in our study
does not exist, we cannot make a direct comparison with FFPE
data, however, in fresh tumor tissue we can routinely detect nearly
200 metabolites with robust signal across central pathways,
including amino acids. While the detection of amino acids was
low in this study, those most frequently detected in our dataset are
acidic and positively charged at physiological pH. The presence of
arginine in fifty-five of the sixty runs further illustrates this point as
one should expect the amino acid with the highest side chain pKa
to be extremely soluble in methanol. We also detected glutamate
and histidine in at least one run for six, and five of the ten samples
respectively. Whether formal charge influences compound extrac-
tion is beyond the scope of this paper, but nevertheless these
observations provide a tangible indication of the classes of
compounds that may be retained or lost during our extraction
protocol.
Reproducibility Assessment
In order to assess the technical consistency across different
injections into the mass spectrometer we calculated each pair-wise
correlation coefficient across three injections for every FFPE
section, excluding only those metabolites that were absent in all
three sections. These values were consistently high for both normal
and tumor tissue indicating that there is little variability between
injections of the same sample preparation. The range of these
correlation coefficients was 0.9373 to 0.9998 with very few under
0.9900 (Figure 2A, B). These complete data can be found in the
Table S1. Next, we calculated the correlation coefficient between
average peak intensities across the two sections from each FFPE
block. Although lower than the values between injections, they still
indicate a high degree of consistency across two sections from the
same block with most correlations higher than 0.9000. Taken
together, we can assert that LC/MS/MS data generated from
FFPE tissue specimens are reproducible with respect to different
injections of the same sample preparations and across different
FFPE sections. A summary of the aforementioned analysis is
presented in Figure 2C. It is important to note that in this part of
our analysis no normalization or missing value imputation was
performed so the concordances measured here reflect those of raw
LC/MS/MS data.
Differentiation between Known Phenotypes
After conducting the assessment of technical reproducibility, we
excluded from further analysis any metabolites absent from $80%
of the sixty LC/MS/MS experiments. The remaining missing
values were then replaced by a value equal to half of the smallest
measurement in the data, and we normalized as described in the
methods section. Using normalized data, we examined the
metabolite content across the tumor/normal pairs. Under the
assumption that within the five sarcoma sub-types there would be
a higher degree of metabolic deregulation, we calculated the
variance for all detected metabolites across all samples with the
hypothesis that the data would be more disperse in the tumors.
Confirming our hypothesis, the variance in metabolite peak
intensity across the tumor specimens was significantly higher than
that of their normal counterparts (24.8% higher mean metabolite
variance in tumors, P,0.05).
Having determined that the global metabolite content is more
heterogeneous within our tumor cohort, we attempted to use
unsupervised hierarchical clustering to investigate whether the
sarcoma specimens would separate from their normal pairs. On
the basis of 119 metabolites that passed the filtering criteria
described above, we observed that the tumors clustered apart from
the normal specimens with one exception. The dendrogram
displayed in Figure 3A shows that one cluster contains four tumors
and one normal specimen, while the other contains four normal
tissue samples and one tumor. We hypothesize that the paired
nature of our cohort may have prevented sample 3 and sample 5
from separating as the tumor and normal tissue samples from the
same patient may be highly similar in metabolite content. Further
examination of the pathology report revealed that the paraffin
block containing normal tissue from patient 3 was contaminated
with some tumor tissue and we reason that this may be why the
pairing of samples from patient 3 was particularly difficult to
break. The results of hierarchical clustering therefore suggest that
a meaningful phenotypic distinction can be made on the basis of
LC/MS/MS data from FFPE tissue.
As an additional method of unsupervised classification, we
performed principal components analysis (PCA) on our cohort
(Figure 3B). A similar phenomenon is observed as in the
hierarchical clustering as the tumor and normal specimens
separate in the first principal component with the exception of
two samples.
Exploration of Differentially Abundant Metabolites
We attempted to elucidate which metabolites may be most
differentially abundant between our sarcoma specimens and their
normal counterparts. To that end, we performed a student t-test
and significance analysis of microarrays (SAM). These two
Metabolomic Profiling in FFPE Cancer Specimens
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presented in Table 2. Overall, we detected eight distinct
differentially abundant metabolites between the two groups that
illustrate the ability to detect differences in biochemical
intermediates across FFPE tissue samples. Notwithstanding the
small sample size, it is noteworthy that metabolites in this short
list, such as cyclic-AMP, have already been shown to be altered in
tumors.
To confirm the relevance of this list, we performed supervised
hierarchical clustering (Figure 4A) and PCA (Figure 4B) using only
LC/MS/MS peak intensities for these metabolites, and indeed, we
observe separation of the tumor/normal pairs.
Figure 1. Flow chart summarizing targeted LC/MS/MS data acquisition.
doi:10.1371/journal.pone.0025357.g001
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Tissue
Considering the treatment conditions of FFPE tissue, one could
reasonably be concerned that metabolites recovered by LC/MS/
MS may restrict analysis to relatively few pathways, with limited
biological relevance. Thus, in order to confirm that the detected
metabolites represent the preservation of a wide range of
biochemical processes, we performed a pathway enrichment
analysis on the entire list of 119 metabolites that passed filtering
criteria (Figure S3). The enrichment analysis uses a list of
compounds as an input and produces a list of known pathways
which are most strongly represented by the input metabolites.
Using our list, we identified a number of potentially impacted
processes, many of which involve cellular energy production,
although we see a wide range of metabolic pathways. This assures
us that our detection of metabolites is not limited to a small subset
of cellular processes, but rather encompasses a wide range of
metabolic activities. It is interesting to note that several of the most
significantly represented pathways - including glycolysis, glutamate
metabolism, and the citric acid cycle - have been studied
extensively in the context of cancer. In glycolysis, five out of
eleven compounds are robustly detected; in glutamate metabolism,
nine of eighteen are measured; and in the TCA cycle, five of
eleven compounds appear in our data. A summary of this
enrichment analysis is reported in Figure 5 and additional
information regarding the specific metabolites detected from four
highly represented pathways is presented in Figure S4 (4A –
Glycolysis, 4B – Pentose Phosphate Pathway, 4C – Citric Acid
Cycle, 4D – Glutamate Metabolism). In addition to the
aforementioned analysis, we also ran the enrichment algorithm
Table 1. Characteristics of specimen cohort.
Sample Year Normal Tissue Type Tumor Type
1 2005 Fibroadipose tissue High grade sarcoma, myogenic differentiation
2 2005 Vein High grade leiomyosarcoma
3 2006 Fibroadipose tissue Monophasic synovial sarcoma
4 2005 Skeletal muscle Biphasic synovial sarcoma
5 2004 Skin and subcutaneous adipose tissue Well-differentiated liposarcoma
Information about the tissue type of each sample pair is provided. The year column refers to the year of surgical resection.
doi:10.1371/journal.pone.0025357.t001
Figure 2. Technical performance summary. A, B) An example of the correlation between MS peak intensities from different sections from the
same FFPE block is shown. C) Presentation of correlation coefficients for biological replicates. A full table with all correlation information is provided
in the supplementary materials.
doi:10.1371/journal.pone.0025357.g002
Metabolomic Profiling in FFPE Cancer Specimens
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25357on our list of eight differentially present compounds and found that
intracellular signaling processes involving cyclic-AMP were
enriched along with several other pathways (see Figure S1). In
contrast to the analysis performed on the full list of detected
compounds, here we examined which pathways are likely to be
altered in tumors compared to normal samples. To emphasize the
key finding of these analyses, the pathways that are represented are
diverse, which suggests that a broad spectrum of biochemical
processes may be reliably interrogated using LC/MS/MS on
FFPE specimens in future clinical studies.
Discussion
Despite technological advances, there has been relatively little
clinical metabolomics research performed on tumor tissue
specimens [5]. And to our knowledge, there have been no
publications demonstrating the successful acquisition of LC/MS/
MS-based metabolomic data from FFPE tissue. In this study we
show that reproducible data can be acquired from soft-tissue
sarcoma sections preserved in paraffin blocks. Moreover, we
demonstrate how these data can be used to probe a paraffin cohort
for biochemical intermediates pertinent to phenotypic differences.
One concern with any LC/MS/MS-based metabolomic
research protocol is the degree to which sample preparation
degrades potential metabolites of interest [11,12]. This challenge is
amplified when one considers damage on the tissue during the
process of formalin fixation and paraffin embedding. Limitations
associated with FFPE tissue include degradation and attrition of
compounds of interest. For instance, it has been shown that
mRNA levels are significantly lower in FFPE preparations
compared with frozen tissue extractions, and one may reasonably
expect an analogous situation to arise in studying metabolites [13].
Therefore, a pipeline of obtaining reliable LC/MS/MS data from
these challenging specimens would be a substantial step towards
accelerating translational metabolomic studies. We observe a non-
trivial degree of attrition of detectable compounds compared to
the same protocol applied on both fresh and frozen tissue [14;
unpublished data]. However, we still detect a substantial number
of polar metabolites extracted from our FFPE cohort. Because
frozen tissue samples from the patients in this study do not exist,
we could not directly compare our data with those generated by
high quality specimens, although this question is worth investigat-
ing in future work.
Other possible factors leading to compound attrition are
degradation during formalin-fixation, loss of compounds during
methanol extraction, and inefficient de-cross-linking of paraffin,
although we cannot say to what degree these factors influence our
detection rates.
Importantly, when we examine the raw data obtained from our
protocol, we find that there is almost no variability between
different injections from the same sample preparation. This assures
us that the sample preparation protocol generates a homogeneous
solution containing a wide range of metabolites. Furthermore, the
tight correlation suggests that there is almost no technical
variability across runs. Of particular importance to investigators
though, is the high degree of correlation observed between
different sections from the same paraffin block. For seven out of
ten blocks, the correlation across sections was higher than 0.95,
and for nine out of ten, it was above 0.90. These results suggest
that measurements of metabolite content in paraffin embedded
tissue may not be limited by a large sampling error.
Figure 3. Unsupervised phenotypic distinction of samples. A) Hierarchical clustering and B) principal components analysis using data from
the set of 119 metabolites passing filtering criteria. In the figures above, tumor specimens are in red and normal specimens are in green.
doi:10.1371/journal.pone.0025357.g003
Table 2. Differentially abundant metabolites identified by
significance analysis of microarrays and by student t-test.
SAM Metabolite D-value P-value T-Test Metabolite P-value
Carbamoyl
phosphate
3.1031 0.013193 cytosine 0.015548
CMP 2.8751 0.020588 Ng,NG-dimethyl-L-arginine 0.023861
ribose-phosphate 2.8668 0.020756 nicotinamide 0.027013
cytosine 2.7854 0.024622 cyclic-AMP 0.027947
cyclic-AMP 2.4982 0.037059
DL-Pipecolic acid 2.301 0.04916
doi:10.1371/journal.pone.0025357.t002
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any ‘‘omics’’ application is the ability to detect known structure
and information in the data. In addition, in the case of
metabolomics one is interested in the breadth of metabolic
pathways involved with the detected compounds. The ability to
use unsupervised methods to accurately classify samples as being
cancerous versus non-malignant is a very good indication of the
value of this application and also suggests that at least a subset of
compounds being detected are true indicators of differential
metabolic activity. It is interesting to note that of the compounds
identified as significantly altered, cyclic-AMP (detected by two
different analytical methods) has been shown to be involved with
several tumorigenic processes [15–17]. Moreover, pathways
involved in cellular energetics – such as glycolysis, pentose
phosphate metabolism, and the citric acid cycle – that have been
implicated in cancer are significantly represented by the set of
metabolites passing filtering criteria [6–8]. We also detected
several phosphorylated metabolites that were identified as
significantly altered, suggesting that phosphorylation may be
better preserved in paraffin tissue than was previously believed.
Taken together, these observations are consistent with the existing
cancer literature and illustrate that many metabolic processes
critical in cancer biology can be interrogated in FFPE tissue using
LC/MS/MS.
To summarize, we have demonstrated the reproducible
acquisition of metabolomic data using LC/MS/MS in SRM
mode from FFPE soft tissue sarcoma specimens. Our data suggest
that larger studies involving a more diverse cohort of malignancies
may be warranted to further establish the reliability and general
utility of the method, and that a wide range of clinical and
biological questions may be successfully investigated with this
methodology in widely available archived specimens.
Materials and Methods
Ethics Statement
This work was done in accordance with a protocol for archival
tissue collection and use which was approved by the Institutional
Review Board (IRB) at Beth Israel Deaconess Medical Center
(BIDMC). The requirement for a patient consent form was waived
by the IRB at BIDMC.
FFPE Sarcoma Specimens
Formalin-fixed and paraffin-embedded tissue samples were
retrieved by the Department of Pathology at Beth Israel Deaconess
Medical Center. The tumor and normal tissue blocks were from
the same patient and were obtained during surgical resection. For
some specimens the tumor and normal tissue type is the same. It is
important to note that for those samples that do not have an
associated normal tissue of origin, e.g. synovial sarcoma, the
normal tissue specimen was taken from areas directly adjacent to
the tumor mass.
Targeted Mass Spectrometry Analysis
From each of ten FFPE blocks, one 40 mm slice was discarded to
minimize contamination of the specimens. The second and third
40 mm sections were then placed in two separate 1.5 mL
microfuge tubes which correspond to the two sections analyzed
from each sample. 1 mL 80% MeOH was added to each slice and
mixed by vortexing. The sections were then incubated for 45
minutes at 70uC to melt the paraffin and extract metabolites. Next,
the samples were placed on ice for 5 minutes, centrifuged in a cold
room for 10 minutes at 14xG and the supernatant was transferred
to a fresh 1.5 mL microfuge tube. The centrifugation was repeated
once under the same conditions and the supernatant was again
transferred to a new tube. The samples were dried by SpeedVac
overnight. Samples were re-suspended using 35 mL HPLC grade
water for mass spectrometry. 10 mL were injected and analyzed
using a 5500 QTRAP triple quadrupole mass spectrometer (AB/
Sciex) coupled to a Prominence UFLC HPLC system (Shimadzu)
via selected reaction monitoring (SRM) of a total of 249
endogenous water soluble metabolites for steady-state analyses of
samples. The 249 compounds monitored were chosen due to their
involvement in central pathways important in a number of
malignancies. Some metabolites were targeted in both positive and
negative ion mode for a total of 298 SRM transitions. ESI voltage
Figure 4. Supervised phenotypic distinction of samples. A) Hierarchical clustering and B) PCA of tumor and healthy specimens using data
from the subset of significantly differentially abundant metabolites identified by t-test or SAM.
doi:10.1371/journal.pone.0025357.g004
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mode. The dwell time was 4 ms per SRM transition and the total
cycle time was 1.89 seconds. Approximately 8–11 data points were
acquired per detected metabolite. Samples were delivered to the
MS via normal phase chromatography using a 4.6 mm i.d
610 cm Amide XBridge HILIC column (Waters) at 300 mL/min.
Gradients were run starting from 85% buffer B (HPLC grade
acetonitrile) to 35% B from 0–3.5 minutes; 35% B to 2% B from
3.5–11.5 minutes; 2% B was held from 11.5–16.5 minutes; 2% B
to 85% B from 16.5–17.5 minutes; 85% B was held for 7 minutes
to re-equilibrate the column. Buffer A was comprised of 20 mM
ammonium hydroxide/20 mM ammonium acetate (pH=9.0) in
95:5 water:acetonitrile. Peak areas from the total ion current for
each metabolite SRM transition were integrated using Multi-
Quant v2.0 software (AB/Sciex). The LC/MS/MS platform was
quality controlled on a daily basis using polar metabolite extracts
from H929 cancer cells. A selected number of metabolites were
assessed using their known chromatographic elution times from
the normal phase column and their expected peak area intensities.
Technical Performance Assessment
Technical reproducibility was assessed across all pairs of
injections of each section of each sample. There were sixty LC/
MS/MS runs in all comprised of three 10 mL injections of each
sample preparation. The Pearson correlation coefficient was taken
between each pair of injections excluding only those metabolites
for which none of the three injections registered a signal. The
average peak intensities across all three injections were then taken
for all metabolites and the Pearson correlation coefficient was
computed across the average peak intensities for both sections
from the same sample, excluding only those metabolites which had
an average value of zero. The average number of metabolites
detected was computed as a mean across all three injections for
every section of every sample.
Figure 5. Summary of pathway enrichment analysis. Above is a display of the diversity of signaling pathways that are enriched on the basis of
all 119 metabolites passing filtering criteria. The most significant p-values are in red while the least significant are in yellow and white.
doi:10.1371/journal.pone.0025357.g005
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The raw peak intensities were uploaded to Metaboanalyst.ca, an
online freeware program intended for the analysis of metabolomic
data [18,19]. Metabolites were first removed from further analysis
if they were absent from $80% of the 10 mL injections. We chose
the cutoff of 80% in order to ensure that we did not exclude
compounds that may be detected exclusively in one class (tumor or
normal). Remaining missing values were calculated as half of the
minimum positive value in the original LC/MS/MS output. The
resultant data were normalized by sum and log2 transformed
before advancing to statistical analysis. The resultant peak
intensity matrix contained 119 unique metabolites which were
used for further analysis. In some cases, LC/MS/MS cannot
distinguish between isomers; we have intentionally omitted
chemical side group position indices for these compounds. For
completeness, we also attempted normalization by median
followed by log2 transformation, which gave nearly identical
results (see Figure S2A and B for hierarchical clustering and PCA
respectively).
Hierarchical Clustering and Principal Components
Analysis
Unsupervised hierarchical clustering using the entire set of 119
metabolites passing filtering criteria was performed using the
Pearson correlation metric and complete linkage. Principal
components analysis was performed according to default settings
on the metaboanalyst interface. Supervised clustering using the
union of metabolites identified by t-test and SAM was done using
the Pearson correlation metric and the Ward linkage method.
Differentially Abundant Metabolite Identification
Differentially abundant metabolites were identified by a student
t-test using a p-value cutoff of 0.05 and also by significance analysis
of microarrays with a delta value of 0.4.
Pathway Enrichment Analysis
Pathway enrichment (representation) analysis was performed
using both the 119 compounds that passed our filtering criteria
and using the union of compound lists identified by the student t-
test and SAM. The metabolite set library used was the ‘‘metabolic
pathway associated metabolite sets,’’ and representation analysis
was done using the hypergeometric test. The output of this
algorithm will mark a metabolic pathway as significantly
represented by the input list of compounds if significantly more
compounds involved with the pathway are present in the input list
than would be expected by random chance. This analysis was
implemented in Metaboanalyst.
Supporting Information
Figure S1 Pathway enrichment analysis summary using
metabolites detected as significantly differentially pres-
ent in tumor and healthy tissue. Significant p-values are in
red while less significant p-values are in yellow or white.
(TIF)
Figure S2 Unsupervised phenotypic distinction of sam-
ples. A) Hierarchical clustering and B) PCA of tumor and healthy
tissue samples using data normalized by median.
(TIF)
Figure S3 Table of pathways represented by 119
metabolites passing filtering criteria. The column labeled
‘‘hits’’ presents the number of metabolites we detect from each
pathway while the column labeled ‘‘total’’ gives the total number
of intermediates in the process.
(TIF)
Figure S4 Pathway representation summary. The dia-
grams above indicate in boldface the metabolites we robustly
detected which are involved in A) glycolysis, B) pentose phosphate
pathway, C) citric acid cycle, and D) glutamate metabolism.
(TIF)
Table S1 Complete summary of pair-wise correlations
across injections for every section. Included for every
section are all pair-wise Pearson correlation coefficients (r) across
three LC/MS/MS injections. The sections are denoted by sample
number.section number_tumor/normal status; so the first slice
from the tumor pair from sample five would be denoted: ‘‘Sample
5.1 Tumor.’’
(DOC)
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